- invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share.
- The proposed acquisition values F-star at approximately $161 million.
- Just a year ago, F-star priced its IPO at $7.
- F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline.
- Four programs are progressing in the clinic, three based on F-star's tetravalent platform and one next-generation STING agonist, with multiple further undisclosed programs in development.
- Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas, including oncology, immunology, and neurology.
- Related: F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen.
- The invoX and F-star Board of Directors have unanimously approved the transaction. It is expected to close in 2H of 2022.
- invoX, established in 2021 in the U.K., is Sino Biopharma's international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.
- Price Action: FSTX shares are up 67.1% at $6.65 during the premarket session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
F-star Therapeutics Shares Are Rallying Today - Read Why
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks